Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Huntington disease
Biotech
UniQure set to resume dosing in open-label Huntington's trial
UniQure's data safety monitoring board has given the green light for dosing to resume in an open-label trial for patients with Huntington's disease.
Max Bayer
Nov 2, 2022 10:18am
3 patients hospitalized in uniQure Huntington's disease trial
Aug 8, 2022 11:45am
Will Annexon's Huntington's data smooth over worried investors?
Jun 7, 2022 6:30am
Sage's Alzheimer's drug may improve cognitive performance
Apr 1, 2022 10:29am
Bon voyage: Voyager Therapeutics' CEO, R&D chief exit
May 20, 2021 3:59am
FDA puts Voyager's Huntington program on hold
Oct 13, 2020 8:35am
